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2Abstract
The endothelial glycocalyx is a key component of the glomerular filtration barrier. We have
shown that matrix metalloproteinase (MMP)-mediated syndecan 4 shedding is a mechanism 
of glomerular endothelial glycocalyx damage in vitro, resulting in increased albumin 
permeability. Here we sought to determine whether this mechanism is important in diabetes
in vivo. We studied early diabetic kidney disease in streptozotocin-induced type 1 diabetes in 
DBA2/J mice. Diabetic mice were albuminuric and had increased glomerular albumin 
permeability and endothelial glycocalyx damage. Syndecan 4 mRNA expression was 
upregulated in isolated glomeruli and flow cytometry-sorted glomerular endothelial cells. In 
contrast, glomerular endothelial luminal surface syndecan 4 and Marasmium oreades 
agglutinin lectin labelling measurements were reduced in diabetes. Similarly, syndecan 4
protein expression was significantly decreased in isolated glomeruli and increased in plasma 
and urine, suggesting syndecan 4 shedding. MMP 2, 9 and 14 mRNA expression were 
upregulated in isolated glomeruli, suggesting a possible mechanism of glycocalyx damage 
and albuminuria. We therefore characterised in detail the activity of MMP 2 and 9 and 
showed significant increases in kidney cortex, plasma and urine. Therapeutic treatment with 
MMP 2/9 inhibitor I at 5mg/kg/day for 21 days, started 6 weeks after diabetes induction,
restored endothelial glycocalyx depth and coverage and attenuated diabetes-induced 
albuminuria and reduced glomerular albumin permeability. MMP inhibitor treatment
significantly attenuated glomerular endothelial and plasma syndecan 4 shedding and inhibited
plasma MMP activity. These studies confirm the importance of MMPs in endothelial 
glycocalyx damage and albuminuria in early diabetes and demonstrate that this pathway is 
amenable to therapeutic intervention. Treatments targeted at glycocalyx protection by MMP
inhibition may be of benefit in diabetic kidney disease.
3Translational Statement
Manipulating glycocalyx, through MMP inhibition, provides an attractive therapeutic target 
in diabetic kidney disease. MMP inhibitor treatment is realistic in the clinical setting:
tetracyclines, an antibiotic agents, inhibit MMPs at sub-antibiotic doses and have been shown 
to have benefits in human disease1, 2 and low dose doxycycline (MMP inhibitor) is licensed 
for the treatment of periodontitis.3 The development of more specific MMP inhibitors 
promises to reduce the adverse effects associated with broad-spectrum MMP inhibitors seen 
in some clinical trials. Shed glycocalyx components including SDC4 warrant further 
investigation as potential biomarkers for diabetic kidney disease and associated 
cardiovascular complications.
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Introduction
Diabetic kidney disease (DKD) is a serious complication of diabetes developing in 
approximately 1 in 3 people with diabetes. The cost of treating diabetic complications,
including DKD, is expected to rise from the current total of £7.7 billion to £13.5 billion by 
2035/6 in the UK.4 Despite this, renin-angiotensin system blockade remains the only 
established treatment in slowing the progression of disease and delaying renal failure. New 
treatments specifically targeting key steps in disease evolution are desperately needed.
The glomerular endothelium is emerging as a key player in diabetes and other glomerular 
diseases.5 The glomerular endothelial cell (GEnC) glycocalyx in particular plays an important 
role in glomerular barrier function.6, 7 The endothelial glycocalyx is a hydrated poly-anionic 
gel present on the luminal surface of all endothelial cells and is composed principally of 
proteoglycans.8 Proteoglycans consist of a core protein, e.g. a syndecan (SDC) and 
4glycosaminoglycan (GAG) side chains, e.g. heparan sulphate (HS). SDC1 and 4 in particular 
are prominent in the kidney.9-12 SDC4 has a short cytoplasmic domain and an ectodomain 
which carries 3-5 HS chains,13-15 and is the most abundant amongst the SDC family in human 
GEnC.16
Endothelial glycocalyx has multiple roles in vascular homeostasis17 and its disruption 
contributes to several vascular diseases including diabetes.6-8, 18 Our group and others have 
shown that the glomerular endothelial glycocalyx contributes to the barrier to albumin 
permeability in cultured cells18-20 and in vivo.21-24 Loss of GAG within the glomerular 
capillary wall is seen in albuminuric diabetic rats25 and diabetic mice.26, 27 In humans 
systemic glycocalyx dimensions are reduced in diabetes.28, 29 Loss of systemic and glomerular 
glycocalyx is associated with the development of microalbuminuria in diabetes, suggesting 
that glycocalyx dysfunction contributes to the pathogenesis of this condition.6, 30
Glycocalyx components are cleaved from the cell surface by ‘sheddases’ including matrix 
metalloproteinases (MMPs).13, 16 Gelatinases MMP2 and 9 can be activated by membrane 
type 1 MMP, also known as MMP14. We and others have shown that diabetic conditions 
induce upregulation of endothelial MMP9,16 MMP229 and urinary MMP1431; their enzymatic 
activities are elevated in diabetic human31, 32 and mouse33 kidneys. The dysregulation of 
MMP 2 and 9 activities has been associated in the pathophysiology of several diabetic co-
morbidities.34-36 Urinary MMP2 and 9 concentration and activity are increased in type 1 
diabetic patients with albuminuria.36-38
We have previously shown that in response to TNFα, an inflammatory mediator which is 
increased in diabetic milieu, SDC4 was specifically and significantly upregulated amongst 
other SDCs in human GEnC in vitro.16 TNFα treatment caused a disruption of the GEnC 
glycocalyx through MMP9-mediated shedding of SDC4 and HS and this was accompanied 
5by an increase in protein permeability across GEnC monolayers.16 Here we seek to determine 
whether this mechanism is important in glomerular disease in diabetes in vivo. We 
hypothesise that GEnC glycocalyx dysfunction in diabetes is caused by MMP-mediated 
shedding of SDC4 and that this is amenable to therapeutic intervention. 
Results
Glomerular endothelial glycocalyx damage accompanies albuminuria in early DKD
DBA/2J mice became hyperglycemic 2 weeks after the first of five daily STZ injections (Fig. 
1 Ai). There was no significant change in body weight in the STZ-treated mice when 
compared to baseline, prior to STZ injection (Fig. 1 Aii). However, the diabetic mice gained 
less weight than control mice, resulting in a 1.2-fold lower body weight after week 8 post 
STZ (Fig. 1 Aii). The mice became significantly albuminuric after week 6 post STZ, and this 
persisted until the mice were culled with a 4.9-fold increase in albuminuria (Fig. 1Bi) at 8 
week post STZ. Compromised glomerular capillary wall integrity was confirmed by a 2-fold
increase in glomerular albumin permeability (Ps’alb) (Fig. 1Bii). Permeability changes were
associated with disruption of the glomerular glycocalyx. There was a 2-fold decrease in 
endothelial glycocalyx depth measured by electron microscopy but no significant change in 
glycocalyx coverage (Fig. 1C, D). Moreover, a decrease in podocyte glycocalyx depth was 
observed but no significant change in other ultrastructural features including glomerular 
basement membrane (GBM) thickness, slit diaphragm and foot process width 
(Supplementary Fig. 1A-E). Moreover, Picrosirius red staining showed no significant 
collagen deposition in diabetes when compared to control (Supplementary Fig. 1F-G), 
confirming the electron microscopy results, suggesting no change in GBM structure. 
Marasmium oreades agglutinin (MOA) lectin bound specifically to the endothelial 
glycocalyx, on the luminal surface of the GEnC (determined using the membrane label R18)
(Fig. 1Ei). We have applied our peak to peak measurement technique, previously used in 
6vivo,39, 40 for the first time on fixed kidney tissue (Figure 1 Eii). Peak to peak measurement of 
MOA labelling, an index of glycocalyx thickness, demonstrated a 1.5 fold reduction in 
endothelial glycocalyx thickness in diabetes which is consistent with the reduction in 
endothelial glycocalyx depth observed by electron microscopy (Figure 1 Eiii).
Glycocalyx-related gene expression is modified in early DKD
Expression of the glomerular glycocalyx-related genes SDCs and glycocalyx modifying 
genes MMPs relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untreated 
mice was determined.  SDC4 mRNA expression was significantly higher than other SDC and 
MMP mRNAs (Fig. 2A), in line with SDC expression in human GEnC.16 The effect of 
diabetes on the expression of different components of the glycocalyx was investigated in
isolated glomeruli using a custom-designed TaqMan qPCR array focused on glycocalyx-
related genes (Fig 2B, Supplementary Table 1) similar to that used previously.16 Expression 
Suite software and 2−ΔΔCT method followed by t-test were used to analyse the array data and 
both methods showed a significant increase in SDC1, 4 and MMP14 mRNA expression 
amongst other significantly modulated gene expression (Fig 2B, Supplementary Table 2). 
SDC1, 3, 4 and MMP 14 were independently validated by real time qPCR demonstrating 
significant upregulation in all of them (Fig. 2C). Although there was no significant increase 
in MMP2 and 9 mRNA expression with the TaqMan qPCR array, because of previous data 
suggesting their importance they were further examined by individual qPCR which showed 
significant increase in MMP 2 and 9 (Fig. 2C). In contrast SDC2 was significantly 
downregulated (Fig. 2C). 
SDC4 mRNA, protein and MMP activity are altered in early DKD
Expression of SDC4 and 1 mRNA specifically in GEnC was determined in cells isolated by 
flow cytometry (Supplementary, Fig 2). SDC4 mRNA expression was upregulated 2.5-fold 
(Fig. 3A) whereas SDC1 mRNA expression was not significantly changed in diabetes (Fig. 
73B). To quantify endothelial glycocalyx SDC4 protein expression, an anti-SDC4 antibody 
was injected intravenously and shown to localise predominantly to GEnC (Supplementary, 
Fig 3). To specifically quantify the SDC4 on the luminal surface of the endothelial cells, we 
have used R18 labelling to highlight the endothelial membrane and enable separation of 
luminal from non-luminal labelling. Peak to peak measurement demonstrated a 2.8-fold 
reduction in glomerular endothelial glycocalyx SDC4 in diabetes (Fig. 3C). Similarly, SDC4 
expression by ELISA was reduced 1.6-fold in diabetic glomeruli, suggesting glomerular 
SDC4 shedding (Fig. 3D), whereas SDC1 glomerular protein expression was not changed in 
diabetes (Fig. 3E). There was a 1.8-fold (Fig. 3F) and a 11.8-fold (Fig. 3G) increase in 
plasma and urine SDC4 concentration respectively, again consistent with systemic SDC4 
shedding in diabetes. We measured the sheddases MMP2 and 9 and found that active MMP2 
concentration was increased by 2-fold in kidney cortex lysate, 1.5-fold in plasma and 3-fold 
in urine (Fig. 4A-C) and active MMP9 concentration was increased by 1.8-fold in kidney 
cortex lysate, 1.8-fold in plasma and 2.5-fold in urine (Fig 4D-F).
MMP2 and 9 mediate disruption of the glomerular endothelial glycocalyx in early DKD
An MMP 2/9 inhibitor (MMPI) was given therapeutically, after the onset of albuminuria at 
week 6 post STZ, for 21 days (Fig. 5A). Blockade of MMP had no significant effect on 
glycaemia and body weight (Fig. 5B, C) but significantly attenuated the diabetes-induced
increase in urinary albumin creatinine ratio by 2.6-fold (Fig. 5D). MMPI treatment reduced 
the diabetes-mediated increase in Ps’alb by 2-fold, restoring the permeability barrier of the 
glomerular capillaries (Fig. 5E). MMPI also restored diabetes-induced endothelial glycocalyx
loss, evidenced by a 1.6-fold increase in endothelial glycocalyx depth and a 2-fold increase in 
endothelial glycocalyx coverage (Fig. 5F, G). MMPI treatment also resulted in a significant 
increase in podocyte glycocalyx depth, but there was no significant effect on GBM thickness,
nor podocyte foot process and slit diaphragm width (supplementary Fig 3A-E).
8Blockade of MMP2 and 9 ameliorates diabetes-induced changes in SDC4 and reduces 
plasma MMP activity
MMPI treatment restored the decrease in SDC4 labelling by peak to peak measurement 2.2-
fold (Fig. 6A). It attenuated the increase in SDC4 mRNA expression observed in diabetes by
1.5-fold (Fig. 6B) and restored the loss of glomerular SDC4 protein expression by 1.8-fold
(Fig. 6C). MMPI significantly attenuated diabetes-induced plasma SDC4 shedding by 2-fold
but not urine SDC4 shedding (Fig. 6D, E). Therapeutic treatment with MMPI blocked 
diabetes-induced increase in plasma MMP2 and 9 activities by 2-fold and 1.2-fold 
respectively (Fig. 6F, G), confirming that this inhibitor reduces the activity of both MMPs in 
vivo.
Discussion
In this study, we investigated our hypothesis that GEnC glycocalyx dysfunction in diabetes is 
caused by MMP mediated SDC4 shedding and importantly, that is amenable to therapeutic 
intervention. We have used a model of early DKD, week 8-9 post STZ, resulting in the mice 
being hyperglycaemic and albuminuric. Due to tubular reabsorption of filtered albumin and 
changes in local hemodynamics, albuminuria is not a sensitive measure of glomerular 
permeability. Therefore, we have used our reliable, physiologically relevant glomerular 
albumin permeability assay to directly measure glomerular permeability using single 
capillaries in isolated glomeruli. The assay has been extensively validated and provided 
robust, reproducible estimates of glomerular albumin permeability.24 We observed an 
increase in glomerular albumin permeability, confirming reduced glomerular capillary wall 
integrity in early DKD. The increase in albuminuria and in glomerular permeability was 
associated with a reduction in endothelial and podocyte glycocalyx depth without affecting 
other glomerular ultrastructure such as GBM thickness, podocyte slit diaphragm and foot 
process width. Moreover, there was no change in collagen deposition in our model using 
9Picrosirius red staining, this supports the electron microscopy data. Our findings are 
consistent with our previous work showing that at 8 weeks post STZ injection, type 1 diabetic 
mice do not develop GBM thickness and podocyte effacement.41 GBM thickening has been 
reported in some but not all mouse models of diabetic nephropathy.42 For example, GBM 
thickening occurs in diabetic DBA2J mice after ∼25 weeks of hyperglycemia.43 Our data 
confirms previous observations that loss of glomerular glycocalyx, in the absence of changes 
in other glomerular capillary wall components, is associated with albuminuria and glomerular 
permeability in early DKD.24, 27
The role of the podocyte glycocalyx has not previously been examined in detail so further 
work is necessary to determine the significance of our observation of podocyte glycocalyx 
loss in diabetes. Some studies support the hypothesis that endothelial activation can lead to 
secondary podocyte injury.44-47 It has been shown that damage specifically to the glomerular 
endothelial glycocalyx using hyaluronidase results in extensive uptake of albumin by
podocytes, which could initiate an inflammatory reaction resulting in podocyte damage.48, 49
In this study, we observed endothelial and podocyte glycocalyx damage, however the damage
to podocytes was not severe enough to cause foot process effacement in this model of early 
DKD.
MOA lectin, known to bind to specific carbohydrate sequences present in the glycocalyx of 
mouse glomerular endothelium,50, 51 was used to specifically study the glomerular endothelial 
glycocalyx. Consistent with previous findings,50, 51 MOA lectin localised to the glomerular 
endothelial glycocalyx; and our peak to peak measurement technique,39, 40 demonstrated a 
reduction in endothelial glycocalyx thickness in diabetes, which complements and supports 
the electron microscopy data. The peak to peak measurement using MOA lectin labelling is 
greater than the glycocalyx thickness by electron microscopy. This is likely to be due to 
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endothelial glycocalyx collapse with the dehydration procedure that follows fixation in 
preparation for electron microscopy.52
The glycocalyx is a complex structure and which components are damaged in diabetes has 
not been previously defined. We show here that in untreated control mice, SDC4 mRNA was 
highly expressed in isolated glomeruli, which is in line with the SDC4 mRNA expression in 
human ciGEnC.16 Custom designed qPCR array focusing on glycocalyx-related genes was 
used to determine the effect of diabetes on glomerular glycocalyx components. Proteoglycan 
SDC1 and 4 mRNA expression were considerably upregulated in isolated glomeruli in DKD. 
This is consistent with another study showing a 26-fold increase in renal/glomerular SDC4 
mRNA in proteinuric DKD.53 Furthermore, by using fluorescence activated cell sorted 
(FACS) mouse GEnC, we were able to show that SDC4 mRNA expression was specifically 
upregulated in this cell type. Our previous work on cultured human GEnC indicate that this 
SDC4 mRNA upregulation is a compensatory response to SDC4 shedding.16 Indeed in line 
with the MOA lectin results, we showed a reduction in glomerular endothelial SDC4 peak to 
peak measurement in DKD. Similarly, glomerular glycocalyx SDC4 protein expression was 
considerably reduced in DKD, suggesting shedding of glomerular endothelial glycocalyx 
SDC4. This was also accompanied by an increase in plasma and urine SDC4 suggesting 
systemic glycocalyx shedding. Other glycocalyx components, including SDC1 concentration,
have already been reported to be increased in serum from subjects with type 1 diabetes 
mellitus and microalbuminuria.54 SDC4 is unlikely to be the only constituent that is being 
shed from the glycocalyx in diabetes. SDC4 carries HS side chains so HS shedding is likely 
to accompany SDC4 shedding as we have shown previously in vitro16 and others have shown 
in vivo in a diabetes model.55 Glycocalyx component hyaluronan56 has also been shown to be 
shed in diabetes. 
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We then determined the underlying mechanism of SDC4 shedding in DKD. MMP2 and 9 are
known to increase in human type 1 and type 2 diabetes57-60 and their levels are altered in 
animal DKD models.31, 32, 38, 60 In this study, we characterised in detail expression of relevant 
sheddases in different compartments and showed that MMP2 and 9 were upregulated at the 
mRNA level and their activities were enhanced in kidney cortex, plasma and urine in DKD.
We also observed an increase in MMP14 mRNA expression in DKD, which was not 
surprising considering MMP14 is a known gelatinase activator.61 The increase in MMP 
activity was associated with loss in GEnC glycocalyx and an increase in albuminuria, 
suggesting that MMP could be the underlying mechanism in SDC4 ectodomain shedding. It 
is likely that MMPs have other targets, and that SDC4 loss is one of them. Indeed, MMPs 
mediate degradation of other proteoglycans,62 SDC1,63 tight junction protein ZO-164 and the 
antioxidant enzyme superoxide dismutase.63 MMPs may also degrade collagens but we did
not find any evidence of this in our model of early DKD. Published findings supports that 
MMPs mediate degradation of endothelial glycocalyx65-68 and is consistent with published 
work highlighting MMP2 and 9 cleavage sites on the SDC4 ectodomain.69
To determine whether endothelial glycocalyx could be protected or restored in DKD, a 
pharmacological approach was adopted, and MMPI, a highly selective inhibitor for MMP2
and 970 was given therapeutically after the onset of albuminuria. MMPI had no effect on 
blood glucose, body weight but significantly attenuated the increase in albuminuria. Our 
glomerular permeability assay confirmed that MMPI reduced the increase in albuminuria by 
decreasing glomerular albumin permeability in DKD, highlighting the usefulness of our novel 
assay in detecting benefits of treatments in terms of glomerular permeability. A study carried 
out in MMP9 deficient mice has shown significant attenuation of albuminuria and 
hyperfiltration in diabetic nephropathy but without determining its effects on the 
glycocalyx.33 We have shown that MMPI treatment protected endothelial glycocalyx by 
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significantly increasing glycocalyx depth and coverage. The inhibitor had no effect on 
glomerular ultrastructure including GBM thickness, podocyte foot process and slit diaphragm 
width. This was as expected given that we did not observe changes in these parameters in our 
model of early DKD. This data is consistent with our previously published work that 
treatment with vascular endothelial growth factor A165b and angiopoietin-1 reversed damage 
to the glomerular endothelial glycocalyx and normalised glomerular permeability in early 
DKD.24, 27 Moreover, VEGFC also protected against raised glomerular permeability and 
ameliorated glycocalyx disruption in diabetic glomeruli.41
Blockade of MMP2 and 9 attenuated diabetes-induced changes in glomerular endothelial 
glycocalyx SDC4, glomerular SDC4 at the mRNA and protein levels, suggesting a reduction 
in glomerular endothelial SDC4 shedding. We previously observed similar effects in human 
GEnC, where MMP inhibition attenuated SDC4 mRNA synthesis and SDC4 shedding and, 
resulting in a reduction in albumin permeability.16 MMPI attenuated diabetes-induced SDC4 
shedding in the plasma but not urine. Our data shows that MMPI has reached the podocytes 
as it restored the podocyte glycocalyx loss observed in diabetes. So, this suggests that there 
are potentially different mechanisms contributing to SDC4 shedding in the plasma and urine; 
the latter being resistant to MMP2 and 9 inhibitor, perhaps other proteases might be 
responsible for SDC4 shedding in the urine. Future work will determine the relative 
importance of MMP2 or 9 and their potential cellular sources. We have previously shown in 
vitro that MMPs produced by GEnC are sufficient to cause SDC4 shedding16 but circulating 
immune cells also produce MMPs71, 72 which may be equally or more important in diabetes in 
vivo. There a number of upstream signalling pathways (MAP Kinases,73, 74 NFκB and PKC65
that have been implicated in MMP activation but there is little context-specific information 
and further work in this area may identify further targets for therapeutic intervention. For 
example, we have previously shown that TNFα activates MMPs and TNF inhibitor used in 
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clinical practice (Etanercept) attenuates glycocalyx loss in an experimental endotoxin 
model.75
Disruption of the endothelial glycocalyx is known to increase albumin excretion in vivo23 and 
in vitro.16, 20 Endothelial glycocalyx protection or restoration is therefore an attractive 
therapeutic target not least because the endothelial glycocalyx damage occurs early in DKD
when microalbuminuria is present but glomerular ultrastructure is otherwise unaffected, as 
we show here. Treatment at this stage may prevent down-stream consequence of developing 
albuminuria. We have demonstrated that MMP2 and 9-mediated SDC4 shedding is the 
underlying mechanism of endothelial glycocalyx damage in DKD and that this pathway is 
potentially amenable to therapeutic intervention. 
Methods
Animal welfare
All animal experiments were approved by the UK Home Office. Male DBA/2J, 6-week-old 
(20–25 g) mice, purchased from Charles River UK Limited, Kent, England, were maintained 
in an environment with controlled temperature (21–24°C) and lighting (12:12h light–dark 
cycle). Standard laboratory chow and drinking water were provided ad libitum. A period of 1-
2 weeks was allowed for animals to acclimatise before any experiments.
Type 1 diabetes model
For induction of diabetes, mice were fasted for 4-6 hours before using the low-dose Diabetic
Complications Consortium (DiaComp) protocol.42 Briefly, streptozotocin (STZ) was given 
intraperitoneally at 50mg/kg for 5 consecutive days and the mice were culled at 8 or 9 weeks 
post STZ injection. Glycaemia, by tail-tip blood droplet analysis using a glucometer (ACCU-
CHEK Aviva, Roche, Switzerland) and body weight were monitored weekly after STZ. STZ-
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injected mice with glycaemia ≥ 15mM were considered diabetic and included in the study. 
The mice were placed in metabolic cages for up to 4 hours to collect urine weekly. Urinary 
albumin was quantified with a mouse albumin ELISA (Bethyl Laboratories, Inc.
Montgomery, TX), and creatinine was measured using an enzymatic spectrophotometric 
assay (Konelab T-Series 981845; Thermo Fisher Scientific, Vantaa, Finland). Urinary 
albumin-to-creatinine ratio (uACR) was calculated as previously.27 At 6 weeks after STZ 
administration, some mice were given daily intraperitoneal injections of a potent and highly 
selective MMP2/9 inhibitor (MMPI) biphenylylsulfonylamino-3-phenylpropionic acid40, 70, 76, 
77 (444241, Merck, Middlesex, UK) at 5mg/kg or vehicle (0.05% DMSO in PBS) for 21 days
and the mice were culled at 9 weeks. MMPI binds to the zinc ion at the active site of MMP2 
and 9, thereby blocking their activities.78
For more details on MMPI and tissue collection in Type 1 diabetes model, please see 
supplementary methods.
Glomerular albumin permeability (Ps’alb) assay 
The glomerular Ps’alb assay was carried out as previously.24 Briefly, Ringer-perfused kidney 
was sieved in 4% BSA in Ringer solution. Isolated glomeruli were incubated in 36.5µg/ml 
Octadecyl rhodamine B chloride (R18, O246, ThermoFisher Scientific) for 15 minutes, then
washed in 4% Ringer BSA to remove unbound R18 followed by 15 minutes incubation in 
30µg/ml AlexaFluor 488-BSA (A13100, ThermoFisher Scientific). An individual glomerulus 
was trapped on a custom-made petri-dish and the perfusate was switched from 30µg/ml 
labelled 488-BSA to 30µg/ml unlabelled BSA. A Nikon TIE inverted confocal microscope was 
used to capture the fluorescence intensity. The rate of decline in fluorescence intensity within 
the loop of the capillaries for the first minute was used to calculate Ps’alb as previously.24
15
Please see supplementary methods for Electron microscopy, Fluorescence Activated Cell 
Sorting (FACS), RNA extraction, Real-time PCR and TaqMan qPCR array.
Protein extraction
Isolated glomeruli were homogenised in PBS. Three freeze-thaw cycles were performed to 
break the cell membranes and the homogenates were centrifuged for 5 minutes at 5000g, at 2-
8°C. The supernatant was removed and either assayed immediately or stored at -80°C.
SDC4 ELISA
The concentrations of SDC4 (ectodomain) in mouse glomerular lysate, plasma and urine 
were quantified using a sandwich enzyme immunoassay (mouse SDC4 ELISA kit, CSB-
EL020891MO, Cusabio, Houston, USA) according to the manufacturer’s instructions. The 
concentration of SDC4 was normalized to total protein content as applicable. The fold change 
of diabetic with MMPI relative to diabetic vehicle was calculated to enable pooling of results 
from different experiments.
MMP2 and 9 activity assays
MMP2 and 9 Biotrak Activity Assays (GE Healthcare Life Sciences, Buckinghamshire, UK) 
provide precise quantitation of active MMP2 and 9 in plasma, urine and tissue homogenates. 
The assays were carried out according to the manufacturer’s instructions. The concentration 
of active MMP2 and 9 was normalized to total protein or creatinine concentration as
applicable.
Lectin staining
5 µm paraffin-embedded kidney sections were dewaxed in histoclear followed by rehydration 
in graded ethanol and a wash is PBS. The sections were incubated in blocking buffer [1% 
BSA in PBS containing 0.5% Tween (PBX)] for 30 min, followed by endogenous biotin 
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blocking using a streptavidin/biotin blocking kit (SP-2002, Vector Laboratories). After 2 
washes, the sections were incubated with biotinylated MOA (2mg/ml) 1:100, pH 6.8 
overnight at 4°C. Buffer only was used as a negative control. After 4 washes, the sections 
were incubated with streptavidin AF488 (S32354, ThermoFisher Scientific, 1:500), pH 6.8, 
for 1 hour at room temperature. The nuclei were counterstained with DAPI (Invitrogen; Life 
Technologies) and the cell membrane labelled with R18 (O246, ThermoFisher Scientific, at 
1:1000 dilution), incubating for 10 min. After a 2 min wash in PBS, the coverslips were 
mounted in Vectashield mounting medium (Vector Laboratories) and examined using either 
an AF600 LX wide-field fluorescence microscope (Leica Microsystems, Milton Keynes, UK) 
or a Leica SP5-II confocal laser scanning microscope attached to a Leica DMI 6000 inverted 
epifluorescence microscope.
Endothelial glycocalyx depth: Peak to Peak analysis
The peak to peak assessment was carried out as.39, 40 A line (white arrow Fig1Ei) was drawn 
from the inside to the outside of the capillary loop crossing the glycocalyx first followed by 
the R18 endothelial membrane. The line is drawn perpendicular to the endothelial glycocalyx 
and the cell membrane label to get the maximum consistent depth of the glycocalyx.
Fluorescence intensity profiles were then generated for both the SDC4 or MOA component 
of the endothelial glycocalyx and endothelial cell label. The distance between the peak 
signals from the SDC4/MOA-488 and the R18 labels (peak to peak: P-P) is an index of 
glycocalyx thickness. P-P was determined from an average of 3 lines in a loop, 3 loops in a 
glomerulus, 3 glomeruli in a mouse and n=5 mice in each group. 
Statistical analysis
Data are expressed as the mean ± SEM. Fold change is defined as the ratio between the two 
groups specified in the text. Normality was assessed using GraphPad Prism 5 Kolmogorov–
17
Smirnov test. Normally distributed data was compared using t-tests for 2 groups and analysis 
of variance (ANOVA) for multiple groups. If one-way ANOVA indicated a significant 
difference, the Bonferroni post hoc test was used to assess differences between groups. 
Where normality could not be demonstrated, the Mann-Whitney test was used for comparing 
between 2 groups.  A p value of <0.05 was considered to indicate statistical significance.
Disclosure
There is nothing to disclose.
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Supplementary Material
Figure S legends
Figure S1. Early diabetic kidney disease (DKD) is associated with reduced podocyte 
glycocalyx but not change in other podocyte or GBM parameters. Control and diabetic mice 
were perfusion-fixed for electron microscopy with cacodylate buffer containing 
glutaraldehyde and Alcian blue. Representative electron micrographs of the glomerular 
capillary wall are shown at lower and higher magnification (Ai, ii). The measurements were 
carried out on 3 capillary loops per glomerulus and 2–3 glomeruli were used per mouse.
Labels indicate podocyte glycocalyx (pGLX), basement membrane (GBM, 1), podocyte slit 
diaphragm width (2) and podocyte foot process width (3) (scale bar =200nm). Quantification 
of (A, Bi) pGLX depth (control 23.70 ± 2.341 n=5 mice, diabetes 15.06 ± 1.713 n=5 mice, 
*p=0.0176) and (A, Bii) percentage podocyte with GLX coverage (control 97.78 ± 2.222 n=5
mice, diabetes 79.28 ± 10.57 n=5 mice, non significant (ns)); (A, C) GBM thickness (control 
134.2 ± 3.047 n=5, diabetes 138.2 ± 10.89 n=5 mice, ns). (A, D) podocyte slit diaphragm 
width (control 40.48 ± 1.914 n=5 mice, diabetes 39.79 ± 3.243 n=5 mice, ns); (A. E) 
podocyte foot process width (control 251.8 ± 17.07 n=5 mice, diabetes 264.9 ± 20.16 n=5
mice, ns). (F, G) Picro Sirius red staining was carried out on control and diabetic kidney 
sections and representative immunohistochemistry images demonstrate no change in collagen 
deposition in diabetic glomeruli when compared to control (a minimum of 3 glomeruli were 
analysed per mouse, control 836500 ± 175700 n=5 mice, diabetes 1060000 ± 339200 
n=5(ns)). Each dot or square on the graph represents a mouse. Data is expressed as the mean 
± SEM and unpaired t test at week 9 post STZ was used for statistical analysis.
Table S1. List of glycocalyx related genes represented on custom-designed TaqMan qPCR 
array
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Table S2. Expression Suite software and 2−ΔΔCT method followed by t test were used to 
analyse the array data and both methods showed a significant increase in SDC1, 3, 4 and 
MMP14 mRNA expression amongst other significantly modulated gene expression.
Table S3. List of primer probes used in this study
Figure S2. Isolation of mouse glomerular endothelial cells. Mouse glomeruli were isolated 
by sieving and were digested with collagenase. The single cells obtained were 
immunolabelled with anti-CD31 antibody. The cells were also stained with propidium iodide 
to exclude the dead ones. Propidium iodide negative and CD31 positive cells (within the 
gate) were sorted by a flow cytometry cell sorter to produce pure population of glomerular 
endothelial cells. The mRNA expression of VEGFR2 (specific for endothelial cells), nephrin 
(specific for podocyte) and PDGFR2 (specific for mesangial cells), relative to GAPDH was 
determined. The representative graph shows glomerular endothelial cells had high expression 
of VEGFR2 but were negative for nephrin and PDGFR2 confirming no or minimal 
contamination with either podocytes or mesangial cells, n=1 mouse.
Figure S3. Mice were injected intravenously (iv) with 0.05 mg/mouse SDC4 antibody 
(100µl). After 18 min of incubation, cardiac perfusion with Ringer was performed to flush 
out unbound antibody. Kidney was snap frozen for immufluorescence staining. (A) Frozen 
kidney sections were incubated with secondary antibody to SDC4 (Alexa 488, green) and 
DAPI (blue). Representative images show that the SDC4 antibody localised predominantly to 
the glomeruli in the SDC4 injected mice and no SDC4 staining can be seen in the PBS 
injected mice.(B) Frozen kidney sections from SDC4 antibody (red and green) injected mice 
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were immunostained with CD31 (endothelial, green), podocin (podocytes, red) and DAPI 
(blue). Representative confocal images show SDC4 colocalises predominantly with 
endothelial and not podocyte markers.
Table S4 shows the absolute values of albumin, creatinine and albumin creatinine ratio from 
3 independent experiments carried out on diabetic (Dia) + MMPI or vehicle (Veh) mice.
Figure S4. Blockade of MMP2 and 9 restored diabetes-induced podocyte glycocalyx loss 
without affecting other podocyte parameters. Diabetic (Dia) ± MMPI or vehicle (Veh)-treated 
mice were perfusion-fixed for electron microscopy with cacodylate buffer containing 
glutaraldehyde and Alcian blue. Representative electron micrographs of the glomerular 
capillary wall are shown at lower and higher magnification (Ai, ii). The measurements were 
carried out on 3 capillary loops per glomerulus and 2–3 glomeruli were used per mouse. 
Labels indicate podocyte glycocalyx (pGLX), basement membrane (GBM, 1), podocyte slit 
diaphragm width (2) and podocyte foot process width (3) (scale bar =100nm). Quantification 
of (A, Bi) pGLX depth (Dia Veh 14.88 ± 1.121 n=5 mice, Dia MMPI 25.16 ± 2.777 n=6 
mice, *p=0.0112) and (A, Bii) percentage podocyte with GLX coverage (Dia Veh 90.60 ± 
8.402 n=5 mice, Dia MMPI 97.30 ± 1.746 n=6 mice, non significant (ns)); (A, C) GBM 
thickness (Dia Veh 154.1 ± 9.837 n=5 mice, Dia MMPI 149.3 ± 7.904 n=6 mice, ns); (A, D) 
podocyte slit diaphragm width (Dia Veh 40.12 ± 4.965 n=5 mice, Dia MMPI 35.42 ± 1.155 
n=6 mice, ns); (A. E) podocyte foot process width (Dia Veh 302.5 ± 26.76 n=5 mice, Dia 
MMPI 244.3 ± 13.21 n=6 mice, ns). Each dot or square on the graph represents a mouse. 
Data is expressed as the mean ± SEM and unpaired t test at week 9 post STZ was used for 
statistical analysis. 
Supplementary information is available at Kidney International's website
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Figure legends
Figure 1. Glomerular endothelial glycocalyx damage accompanies albuminuria in early 
diabetic kidney disease (DKD). Streptozotocin (STZ) was given for 5 consecutive days. Two 
weeks after the first STZ injection, mice became hyperglycemic which persisted until the 
mice were culled after week 8 post STZ. (Ai) Glycemia at week 2 (control 6.717 ± 0.1278 
n=12 mice, diabetes 19.78 ± 1.441 n=12 mice, *** p<0.0001) and week 8 post STZ (control 
6.750 ± 0.1517 n=6 mice, diabetes 28.22 ± 1.586 n=6 mice, *** p<0.0001). (Aii) Body 
weight, not significant (ns) (n=6 mice each group) when compared to baseline (prior to STZ 
injection) but significantly lower than control mice at week 8 post STZ (control 30.08 ± 
0.9420 n=6 mice, diabetes 24.88 ± 0.7641 n=6 mice, ** p=0.0016). (Bi) Urinary albumin 
creatinine ratio (uACR) was determined post STZ injection. Week 6 (control 43.94 ± 6.073 
n=5 mice, diabetes 243.1 ± 77.26 n=5 mice, *p=0.0332), week 7 (control 43.21 ± 5.644 n=12 
mice, diabetes 209.4 ± 67.88 n=10 mice, *p=0.0143) and week 8 post STZ (control 42.81 ± 
3.352 n=10 mice, diabetes 208.3 ± 67.74 n=10 mice, *p=0.0253). (Bii) Isolated glomeruli 
from control and diabetic mice were incubated with R18 then Alexa Fluor 488 bovine serum 
albumin (AF488-BSA), and glomerular albumin permeability (Ps’alb) was measured at week 
9 post STZ. Data is presented as control 3.249 ± 0.2063 n=25 glomeruli, diabetes 5.806 ± 
0.3553 n=22 glomeruli, *** p<0.0001. The data was also analysed in terms of mouse number 
at week 9 post STZ (control 3.144 X10-7 ± 2.947 X10-8 n=5, diabetes 5.857 X10-7 ± 2.788 X 
10-8 n=5 mice, *** p<0.0001. (1C) Representative electron micrographs of the glomerular 
capillary wall are shown. The measurements were carried out on 3 capillary loops per 
glomerulus and 2–3 glomeruli were used per mouse. Labels indicate endothelial glycocalyx 
(eGLX), glomerular basement membrane (GBM) and podocyte glycocalyx (pGLX) (scale 
bar=200nm).  Quantification at week 9 post STZ of (Di) endothelial glycocalyx (eGLX) 
depth (control 24.21 ± 2.550 n=5 mice, diabetes 12.69 ± 1.755 n=5 mice, * * 0.0059); (Dii) 
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percentage endothelium with GLX coverage (control 95.19 ± 2.139 n=5 mice, diabetes 63.32 
± 15.35 n=5 mice, (ns) non significant). (1Ei) Control and diabetic sections were stained with 
Marasmium oreades agglutinin (MOA) lectin and endothelial membrane label R18. 
Representative image shows glomerular capillaries labelled red (R18) and the luminal 
endothelial glycocalyx labelled green (MOA). (Eii) Peak to Peak assessment of the 
glomerular endothelial glycocalyx at week 9 post STZ showed a significant reduction in 
glycocalyx thickness in diabetes (control 336.0 ± 26.33 n=5 mice, diabetes 219.0 ± 38.82 n=5 
mice, * p=0.04). Each dot/triangle/square on the graph represents a mouse. Data is expressed 
as the mean ± SEM and unpaired t test was used for statistical analysis. 
Figure 2. Glycocalyx-related gene expression is modified in early diabetic kidney disease 
(DKD). (A) Glomerular mRNA expression of SDCs and MMPs relative to GAPDH from 
control mice was determined. *** p<0.0005, one way ANOVA with Bonferroni as a post hoc 
test at week 8 post STZ, n=6 mice for all the genes except n=4 mice for MMP 14. (B) A 
custom-designed TaqMan qPCR array was used to identify changes in glycocalyx-related 
gene expression in DKD. The 2−ΔΔCT method of quantification was used to calculate the fold 
change relative to control, * p<0.05, ** p<0.005, unpaired t test (control n=6 mice, diabetes 
n=4 mice for all the genes except control n=4 mice, diabetes n=4 mice for MMP14 and 
diabetes n=3 mice for MMP 9). (C) Genes of interest were validated using independent qPCR 
(control n=6 mice, diabetes n=4 mice), * p<0.05, ** p<0.005, ***p<0.0005, unpaired t test at 
week 8 post STZ. Each dot on the graph represents a mouse. 
Figure 3. SDC4 mRNA and protein are altered in early diabetic kidney disease (DKD). 
Glomerular endothelial cells (GEnC) were sorted by FACS and (A) SDC4 and (B) SDC1 
mRNA expression were determined. The 2−ΔΔCT method of quantification was used to 
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calculate the fold change, normalised to GAPDH, at week 8 post STZ, (SDC4: control 1.000 
± 0.2565 n=9 mice, diabetes 2.470 ± 0.6580 n=8 mice, * p<0.05 ; SDC1: control 1.000 ± 
0.1112 n=5 mice, diabetes 1.663 ± 0.4289 n=5 mice, non significant (ns)). Control and 
diabetic kidney sections were labelled with SDC4 (green) and endothelial membrane label 
R18 (red). (C) Peak to Peak assessment of the glomerular endothelial glycocalyx using SDC4 
labelling at week 9 post STZ showed a significant reduction in glycocalyx SDC4 in diabetes 
(control 182.5 ± 12.04 n=5 mice, diabetes 64.31 ± 6.513 n=5 mice, *** p<0.0001). Isolated 
glomerular lysates from control and diabetic mice were used to determine (D) SDC4 and (E) 
SDC1 concentration using SDC4 & 1 ectodomain ELISA. The data was then normalised to 
total protein content. SDC4 (control 1.327 ± 0.1439 n=6 mice, diabetes 0.8059 ± 0.1218 n=6 
mice, * p<0.05; SDC1 (control 9.671 ± 1.742 n=6, diabetes 9.699 ± 1.313 n=6 mice, non 
significant (ns)) at week 8 post STZ. SDC4 shedding in the (F) plasma and (G) urine was 
determined in DKD using the SDC4 ectodomain ELISA at week 8 post STZ. For plasma, 
control 2.631 ± 0.2860 n=6 mice, diabetes 4.801 ± 0.3793 n=6 mice, **p<0.005. Urine SDC4 
was normalised to creatinine (control 3.343 ± 0.9410 n=4 mice, diabetes 39.32 ± 13.03 n=4 
mice, * p<0.05, Mann Whitney test at week 8 post STZ). Each dot or square on the graph 
represents a mouse. Data is expressed as the mean ± SEM and unpaired t test was used for 
statistical analysis unless specified. 
Figure 4. MMP activity is altered in multiple compartments in early diabetic kidney disease 
(DKD). Renal cortex lysates from control and diabetic mice were used to determine (A) 
MMP2 (control 5.462 ± 0.3652, n=4 mice, diabetes 9.797 ± 1.753, n=6 mice) and (D) MMP9 
(control 41.34 ± 3.85, n=4 mice, diabetes 73.12 ± 9.85, n=6 mice) activities using MMP2 and 
9 biotrak activity assays. The data was then normalised to total protein content at week 8 post 
STZ, ** p=0.0095, Mann Whitney test, ** p=0.037, unpaired t test were carried out 
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respectively. Systemic circulation of (B) plasma MMP2 (control 2.232 ± 0.2873 n=11 mice, 
diabetes 3.285 ± 0.3760 n=10 mice *p=0.0365), (C) urine MMP2 (control 0.03142 ± 0.01251 
n=6 mice, diabetes 0.1002 ± 0.01577 n=10 mice ** p=0.0091), (E) plasma MMP9 (control 
1.053 ± 0.1014 n=6 mice, diabetes 1.920 ± 0.2262 n=6 mice ** p=0.0058) and (F) urine 
MMP9 (control 0.1264 ± 0.03644 n=5, diabetes 0.3196 ± 0.03456 n=10 mice ** p=0.0080 
Mann Whitney test) activities were determined  in DKD. Urine MMP2 and MMP9 were 
normalised to urine creatinine at week 8 post STZ. Each dot or square on the graph represents 
a mouse. Data is expressed as the mean ± SEM and unpaired t test was used for statistical 
analysis unless specified. 
Figure 5. MMPs mediate disruption of the glomerular endothelial glycocalyx in early 
diabetic kidney disease (DKD). (A) Schematic overview of the procedure, 5 daily injections 
of STZ was given at week 0. Six weeks post STZ injection, MMP2/9 inhibitor (MMPI) was 
given for 21 days and mice were culled at week 9 post STZ injection. MMPI had no 
significant effect on (B) glycemia (Dia Veh 31.43 ± 0.8017 n=13 mice, Dia MMPI 31.09 ± 
0.6403 n=14 mice, non significant (ns)) and (C) body weight (Dia Veh 23.88 ± 1.044 n=13 
mice, Dia MMPI 24.83 ± 0.9469 n=14 mice, ns). (D)Treatment with MMPI reduced urine 
albumin creatinine ratio (uACR) (Dia Veh 1.000 ± 0.2093 n=18 mice, Dia MMPI 0.3925 ± 
0.077 n=13 mice * p=0.0172, Mann Whitney test at week 9 post STZ). The fold change of 
diabetic MMPI relative to diabetic vehicle was calculated to enable pooling of results from 
different experiments. (E) Isolated glomeruli from diabetic (Dia) + MMPI or vehicle (Veh) 
mice were incubated with R18 then Alexa Fluor 488 bovine serum albumin (AF488-BSA), 
and glomerular albumin permeability (Ps’alb) was measured. Data is presented as Dia Veh 
6.438 ± 0.4302 n=10 glomeruli, Dia MMPI 3.081 ± 0.4858 n=10 glomeruli, *** P<0.0001. 
The data was also analysed in terms of mouse number (Dia Veh 6.533 X 10-7 ± 2.450 X 10-8 n 
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=3, 3.035 X 10-7 ± 2.963 X 10-8 n=3 mice, *** p=0.0008). (F) Diabetic (Dia) + MMPI or 
vehicle (Veh) mice were perfusion-fixed for electron microscopy with cacodylate buffer 
containing glutaraldehyde and Alcian blue. Representative electron micrographs of the 
glomerular capillary wall are shown. The measurements were carried out on 3 capillary loops 
per glomerulus and 2–3 glomeruli were used per mouse. Labels indicate endothelial 
glycocalyx (eGLX), glomerular basement membrane (GBM) and podocyte glycocalyx 
(pGLX) (scale bar =100nm).  Quantification of (Gi) endothelial glycocalyx (eGLX) depth 
(Dia Veh 20.69 ± 0.5772 n=5 mice, Dia MMPI 32.91 ± 4.186 n=6 mice, * p=0.0276). (Gii) 
percentage endothelium with GLX coverage (Dia Veh 52.74 ± 8.411 n=5 mice, Dia MMPI 
92.56 ± 5.383 n=6 mice, ** p=0.0026). Each dot or square on the graph represents a mouse.
Data is expressed as the mean ± SEM and unpaired t test at week 9 post STZ was used for 
statistical analysis unless specified. 
Figure 6. Blockade of MMP2 and 9 ameliorates diabetes-induced changes in SDC4 and 
reduces plasma MMP activity. Diabetic (Dia) + MMPI or vehicle (Veh)-treated kidney 
sections were labelled with SDC4 (green) and endothelial membrane label R18 (red). (A) 
Peak to Peak assessment of the glomerular endothelial glycocalyx using SDC4 labelling at 
week 9 post STZ showed a significant restoration in glycocalyx thickness (Dia Veh 109.2 ± 
9.003 n=5 mice, Dia MMPI 246.0 ± 22.36 n=5 mice, *** p=0.0005). (B) Isolated glomerular 
lysate from diabetic (Dia) + MMPI or vehicle (Veh)-treated mice was used to determine 
SDC4 mRNA expression. The 2−ΔΔCT method of quantification was used to calculate the fold 
change, normalised to GAPDH and relative to Dia Veh, (Dia Veh 1.000 ± 0.089 n=11 mice, 
Dia MMPI 0.6658 ± 0.04849 n=12 mice, ** p=0.0029). (C). Isolated glomerular lysate from 
diabetic (Dia) + MMPI or vehicle (Veh)-treated mice were used to determine SDC4 
concentration with previously used SDC4 ectodomain ELISA. The data was then normalised 
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to total protein content, (Dia Veh 0.6426 ± 0.06780 n=5 mice, Dia MMPI 1.150 ± 0.1634 n=7 
mice, *p=0.0322). MMPI attenuated SDC4 shedding in the (D) plasma (Dia Veh 1.000 ± 
0.1029 n=11 mice, Dia MMPI 0.5449 ± 0.09749 n=9 mice, **p=0.0054),but not in the (E) 
urine (Dia Veh 1.000 ± 0.1895 n=13 mice, Dia MMPI 0.8501 ± 0.1290 n=8 mice, non 
significant (ns)) in DKD. The fold change of diabetic MMPI relative to diabetic vehicle was 
calculated to enable pooling of results from different experiments. (F, G) Plasma MMP2 (Dia 
Veh 3.001 ± 0.3977 n=13 mice, Dia MMPI 1.528 ± 0.4924 n=7 mice, *p=0.0366) and 9 (Dia 
Veh 1.150 ± 0.07157 n=9 mice, Dia MMPI 0.9266 ± 0.03281 n=6 mice, *p=0.0314) 
activities, using MMP2 and 9 biotrak activity assays, were reduced in diabetic (Dia) + MMPI 
group when compared to diabetic (Dia) + vehicle (Veh) group. Each dot or square on the 
graph represents a mouse. Data is expressed as the mean ± SEM and unpaired t test at week 9 
post STZ was used for statistical analysis unless specified. 
Supplementary Methods
Tissue collection in Type 1 diabetes model
Control, diabetic with or without the MMPI inhibitor/vehicle were culled for tissue collection
at 8 or 9 weeks post STZ injection. MMP inhibitor is an N-sulfonyl amino acid derivative 
modified in the amino acid residue and the sulfonamide moiety. Studies carried out on its 
enzymatic activity have shown that the sulfonamide derivatives containing biaryl, triple bond, 
tetrazole, or amide were selective inhibitors of type IV collagenase (MMP-9 and MMP-2) in 
vitro as well as in vivo.S1 This highly potent and selective inhibitor blocks MMP2 (IC50 = 
310 nM) and 9 (IC50 = 240 nM) without affecting other metalloproteinases. S1 MMPI is 
easily absorbed across the gastrointestinal tract. S2, S3 It has been shown to provide protective 
effects in several disease states: reduce brain edema and preserves the Blood Brain Barrier in 
a brain injury model, S4 ameliorates pathogenesis and improves skeletal muscle regeneration 
in muscular dystrophy S2 and attenuates albuminuria in an aldosterone-induced kidney disease 
model. S3
For tissue collection, some mice were anaesthetised with 3.5% isoflurane in 1L/min O2. A 
midline laparotomy was performed, and the abdominal aorta was cannulated with PE-10 
tubing (Becton Dickinson, 427400, Franklin Lakes, NJ) to flush both kidneys with Ringer 
solution (NaCl, 132mM; KCl, 4.6mM; MgSO4-7H2O 1.27mM; CaCl2-2H2O 2mM; 
NaHCO3, 25mM; D(+)glucose, 5.5mM; N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic 
(HEPES) acid, 3.07mM; HEPES sodium salt, 1.9mM, pH 7.40). One kidney was removed for 
glomerular sieving as previously S5 and the other kidney was perfusion-fixed with a solution 
containing 2.5% glutaraldehyde, 0.1M cacodylate and 1% Alcian blue for transmission 
electron microscopy to quantifying endothelial glycocalyx depth and coverage. S6 In other 
mice, instead of perfusion, blood was collected for plasma isolation and the kidneys used for 
glomerular sieving. Some mice were intravenously (iv) injected with 0.05 mg/mouse SDC4 
antibody. After 18 min of incubation, cardiac perfusion with Ringer was performed to flush 
out unbound antibody. Kidney was snap frozen for immunofluorescence staining.
Electron microscopy
Electron micrographs were taken using a Technai 12 electron microscope (FEI, Hillsboro, 
Oregon) and image analysis was carried out as previously in 3 capillary loops per glomerulus 
and 2–3 glomeruli per animal. S5, S6 Briefly, ImageJ software (SciJava software ecosystem, 
Maryland, USA) was used to overlay a grid onto the electron micrograph. The anatomical 
distance from the luminal phospholipid at sequential grid intersections to the furthest point of 
glycocalyx was measured as glycocalyx depth. A glycocalyx depth ≤ 10nm was considered 
uncovered and this was expressed as a percentage of total measurements taken on a grid section. 
Glycocalyx coverage expressed as a percentage = 100% - glycocalyx uncovered%. GBM 
thickness, podocyte foot process width and slit diaphragm width were also measured. 
Observers were blinded to sample identity before analysis.
Fluorescence Activated Cell Sorting (FACS)
Mouse glomeruli were collected from 75µm pore sieves as previously. S5 The glomeruli were 
digested with 1mg/ml collagenases (1, V, VI) (Sigma-Aldrich, Dorset, UK) for 1 hour at 37°C 
in a hybridization oven with constant rotation. After the enzymatic digestion was complete, the 
digest was passed through a 35µm mesh cell strainer (BD falcon 352235, ThermoFisher 
Scientific) to give a single cell suspension. After 3 washes, the cell pellet was resuspended in 
HBSS containing 1mM EDTA, 0.1ul/ml DNAse and 0.3% BSA (Sigma-Aldrich) and 
immunostained with PE Rat Anti-Mouse CD31 antibody (BD Pharmingen, San Jose, CA) at a 
1:50 dilution for 1 hour at 4°C. After 3 washes, the cells were ready for FACS. CD31 positive 
cells were isolated using a Becton Dickinson Influx Cell Sorter (BD Biosciences, San Jose, 
CA). In brief, single viable cells were detected based on laser scatter, trigger pulse width and 
exclusion of the vital dye Propidium Iodide (PI). Cells were excited with 488nm and 552nm 
lasers and fluorescence emissions were captured for PE (552nm 582/29nm BP) and PI (552nm 
710/50 BP) respectively. Controls included were unstained cells and isotype control (Rat 
IgG2a, κ Isotype Control, FITC Goat Anti-Rat Igs, BD Pharmingen).
RNA extraction 
RNA was extracted from isolated glomeruli using an RNeasy Mini kit (Qiagen, Manchester, 
UK) according to manufacturer’s instructions. Then 2μg of total RNA was converted to 
cDNA by a high-capacity RNA to cDNA conversion kit (Applied Biosystems, Foster City, 
CA, USA), according to the manufacturer's instructions. 
Real-time PCR
The mRNA expression of relevant genes was quantified according to the manufacturer’s 
instructions for real-time PCR (StepOnePlus Real-Time PCR System; Applied Biosystems) 
using TaqMan primer probes (Life Technologies, ThermoFisher Scientific) detailed in 
supplementary Table 3. PCRs were performed in duplicate. The 2−ΔΔCT method was used to 
calculate the fold change, normalized to GAPDH.
TaqMan qPCR array
The custom-designed TaqMan Low Density Array (TLDA, Applied Biosystems) is a 384-
well microfluidic card that performs 384 simultaneous real-time PCR. We designed an array 
which included 53 glycocalyx-related and control genes (Table 2, supplementary material). 
cDNA (1:5 dilution) and TaqMan gene expression master mix (Applied Biosystems) were 
used to perform the reaction. In brief, the wells of the TaqMan array contained TaqMan gene 
expression assays that detected the real-time amplification of the specified targets. Relative 
levels of gene expression were determined from the fluorescence data generated during PCR 
using a ViiA7 Real-Time PCR System (Applied Biosystems). Expression Suite software 
(ThermoFisher scientific) which utilises the comparative Cτ (ΔΔCτ) method was used to 
rapidly and accurately quantify relative gene expression across a large number of genes and 
samples. For the selected genes of interest, the 2−ΔΔCT method was also used to calculate fold 
changes, normalized to GAPDH. Independent t-tests with p < 0.05 were used as a screening 
test, and genes that were significantly modulated (and MMP9 in view of previous results) S7
were selected for further analysis by independent real-time PCR. 
Immunofluorescence staining
5 µm cut frozen kidney sections were fixed with 4% paraformaldehyde. The sections were 
incubated in blocking solution [1% bovine serum albumin (BSA) in PBS containing 0.1% 
Tween] for 1 hour. Some sections from the SDC4 (Purified Rat Anti-Mouse Syndecan-4, 
Clone KY/8.2, BD Biosciences) injected mice were incubated with Alexa Fluor™ 488 
secondary antibody (Molecular Probes; Life Technologies). Others were incubated with 
primary antibodies to either CD31 (FITC Rat Anti-Mouse CD31MEC13.3, BD Biosciences 
at 1:100 dilution) or podocin (P0372, Sigma-Aldrich, at 1:500 dilution) in blocking buffer for 
40 min at room temperature. Primary antibody binding was detected by using Alexa Fluor™ 
488 and 633 secondary antibodies (Molecular Probes; Life Technologies). After 3 washes, 
the nuclei were counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; 
Invitrogen; Life Technologies). For peak to peak analysis, the sections were incubated with 
an endothelial cell membrane label R18 (O246, ThermoFisher Scientific, at 1:1000 dilution) 
for 10 min. After a 2 min wash in PBS, the coverslips were mounted in Vectashield mounting 
medium (Vector Laboratories, Peterborough, UK) and examined using either an AF600 LX 
wide-field fluorescence microscope (Leica Microsystems, Milton Keynes, UK) or a Leica 
SP5-II confocal laser scanning microscope attached to a Leica DMI 6000 (Leica 
Microsystems) inverted epifluorescence microscope.
Picrosirius Red Staining
Picrosirius Red Staining was carried out as. S8 Mouse paraffin tissue sections were hydrated 
followed by counterstaining in a 0.1% (w/v) Direct Red 80 powder (SigmaAldrich) in a 1.3% 
saturated aqueous solution of picric acid (VWR Chemicals) for 90 min at room temperature, 
then dehydrated and mounted. Images were taken using a bright-field microscope. Images 
were quantified using Image J. A minimum of 3 glomeruli were analysed per mouse and n=5 
mice per group. Images were converted to RGB images and colour deconvolution was 
performed. Red staining channel was then converted to 8-bit gray scale image and colour 
inverted. Total of 4 background mean gray value measurements were taken. Tracing tool was 
used to draw around glomerulus to measure area and integrated density. Corrected Total Cell 
Fluorescence (CTCF) was then calculated by subtracting the average of background mean 
gray values multiplied by area of glomerulus from glomerular integrated density. CTCF 
values for each mouse were then averaged and plotted.
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Supplementary Table 1: List of glycocalyx related genes represented on 
custom-designed TaqMan qPCR array
Supplementary Table 1
Class Name Symbol
Proteoglycans Syndecan SDC 1, 2, 3, 4
Glypican GPC 1, 5
Biglycan BGN
Heparan sulfate proteoglycan 2 HSPG2
Versican VCAN
Endothelial cell-specific molecule 1 ESM1
Decorin DCN
Lumican LUM
Proteoglycan degrading 
enzymes Matrix metalloproteinase
MMP 2, 3, 7, 9, 14, 
16
ADAM Metallopeptidase Domain ADAM 17
ADAM Metallopeptidase With 
Thrombospondin Type 1 Motif ADAMTS 1, 4
HS-synthesizing 
enzymes Exostoses EXT 1, 2
N-deacetylase/N-sulfotransferase NDST 1, 2
Heparan sulfate 2-O-sulfotransferase HS2ST1
Heparan sulfate 6-O-sulfotransferase HS6ST 1, 2
HS-degrading/modifying 
enzymes Heparanase HPSE
Sulfatase SULF 1, 2
Chondroitin sulfate-
synthesizing enzymes
Chondroitin sulfate N-
acetylgalactosaminyltransferase CSGALNACT 1, 2
Chondroitin sulfate synthase CHSY
GAG biosynthesis Carbohydrate Sulfotransferase CHST 2, 11
Hyaluronan-synthesizing 
enzymes Hyaluronan synthase HAS 1, 2, 3
Hyaluronan-degrading 
enzymes Hyaluronoglucosaminidase 1, 2 HYAL 1, 2
Hyaluronan receptors
Hyaluronan Mediated Motility 
Receptor HMMR
CD44 Molecule (Indian Blood Group) CD44
Sialic acid-modifying 
enzymes
Glucosamine (UDP-N-acetyl)-2-
epimerase GNE
N-Acetylneuraminic acid synthase NANS
Sialidase NEU
Sialoglycoproteins Endomucin EMCN
Podocalyxin-like PODXL 1, 2
Others Thrombomodulin THBD
Housekeeping genes
Glyceraldehyde-3-Phosphate 
Dehydrogenase GAPDH
Eukaryotic 18S rRNA 18S
Actin, β ACTB
Genes Expression Suite software 2−ΔΔCT method followed by t 
test
SDC1 ↑2.5 fold, *p= 0.02 ↑2.6 fold, **p= 0.002
SDC2 ↑1.0 fold, p= 0.80 ↑1.1 fold, p=0.82
SDC3 ↑2.4 fold, **p= 0.006 ↑2.4 fold, **p 0.001
SDC4 ↑1.5 fold, *p=0.032 ↑1.6 fold, *p 0.039
MMP2 ↑6.5 fold, p=0.24 ↑8.3 fold, p=0.11
MMP9 ↑1.0 fold, p=0.40 ↑1.0 fold, p=0.97
MMP14 ↑2.2 fold, **p=0.009 ↑2.2 fold, **p=0.008
Supplementary Table 2: Two complementary methods were used to analyse the qPCR 
array data. Expression Suite software and 2−ΔΔCT method followed by t test were used to 
analyse the array data and both methods showed a significant increase in SDC1, 3, 4 
and MMP14 mRNA expression amongst other significantly modulated gene expression.
Supplementary Table 2
Genes
Interrogated Sequence Translated 
Protein
Exon 
Boundar
y
Assay 
Locatio
n
Amplic
on 
Length
SDC1
RefSeq NM_011519.2 NP_035649.
1
2--3 387 131
SDC2
RefSeq NM_008304.2 NP_032330.
1
3--4 833 113
SDC3 RefSeq NM_011520.3
NP_035650.
2 4--5 1293 51
SDC4 RefSeq NM_011521.2
NP_035651.
1 4--5 469 55
MMP2 RefSeq NM_008610.2
NP_032636.
1 2--3 674 62
MMP9 RefSeq NM_013599.3
NP_038627.
1 12--13 2098 76
MMP14 RefSeq NM_008608.3
NP_032634.
3 1--2 376 61
GAPDH RefSeq
NM_00128972
6.1
NP_0012766
55.1 2--3 117 107
Supplementary Table 3
Supplementary Table 3: List of primer probes used in this study
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Supplementary Table 4
Supplementary Table 4 shows the absolute values of albumin, creatinine and 
albumin creatinine ratio from 3 independent experiments carried out on diabetic 
(Dia) + MMPI or vehicle (Veh) mice. 
Albumin (µg/ml) Creatinine (mmol/L) ACR (mg/mmol)
Dia Veh 45.9 0.91 50.43956044
Dia Veh 35.6 0.4 89
Dia Veh 6.717853 0.41 16.38500732
Dia Veh 17.3 0.28 61.78571429
Dia Veh 18.8 0.37 50.81081081
Dia Veh 94.2 0.47 200.4255319
Dia Veh 15.9 0.32 49.6875
Dia Veh 48 0.8 60
Dia Veh 15.5 0.39 39.74358974
Dia Veh 71.5 0.64 111.71875
Dia Veh 57.2 0.42 136.1904762
Dia Veh 161 0.8 201.25
Dia Veh 167 0.3 556.6666667
Dia Veh 51.2 0.31 165.1612903
Dia Veh 25.4 0.73 34.79452055
Dia Veh 28.6 0.16 178.75
Dia Veh 4.303508 0.23 18.71090435
Dia Veh 7.112287 0.41 17.34704146
Dia MMPI 16.7 0.42 39.76190476
Dia MMPI 33.6 0.58 57.93103448
Dia MMPI 3.232883 0.26 12.43416538
Dia MMPI 12.9 0.5 25.8
Dia MMPI 16.2 0.45 36
Dia MMPI 4.296473 0.58 7.407712069
Dia MMPI 4.284453 0.34 12.60133235
Dia MMPI 63.3 0.92 68.80434783
Dia MMPI 7.083118 0.33 21.46399394
Dia MMPI 37.4 0.3 124.6666667
Dia MMPI 19.8 0.38 52.10526316
Dia MMPI 24.8 0.98 25.30612245
Dia MMPI 41.4 0.3 138
Bi
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C
CONCLUSION:
Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial 
glycocalyx and glomerular filtration barrier function in early diabetic kidney disease
This study confirms the importance of MMPs in 
endothelial glycocalyx damage and kidney 
dysfunction in early diabetes and demonstrates that 
this pathway is amenable to therapeutic intervention. Ramnath et al, 2019
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